Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors

Erectile Dysfunction Clinical Trial

Official title:

A Prospective, Randomized, Double-blind, Double-dummy, Placebo- and Active Controlled, Multicenter Study Assessing the Efficacy and Safety of the Combination BAY60-4552 / Vardenafil Compared to Vardenafil (20 mg) for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 (Phosphodiesterase 5) Inhibitors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01168817
• Other study ID #: 14694
• Secondary ID: 2010-020122-18
• Status: Completed
• Phase: Phase 2
• First received: July 22, 2010
• Last updated: November 3, 2014
• Start date: August 2010
• Est. completion date: May 2011

Study information

• Verified date: November 2014
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesItaly: The Italian Medicines AgencyNetherlands: Medicines Evaluation Board (MEB)Spain: Spanish Agency of Medicines
• Study type: Interventional

Clinical Trial Summary

This study examines the efficacy and safety of the combination treatment BAY60-4552 plus vardenafil in patients with erectile dysfunction, who do not sufficiently respond to therapy with PDE5 (Phosphodiesterase 5) inhibitors.

Patients meeting the entry criteria, will receive vardenafil alone in the first four weeks of the study to assess the effect of PDE5 inhibitor therapy given alone.

Patients with an insufficient therapeutic response to vardenafil alone will enter the next part of the study, and will be randomly assigned to one of 3 treatments. There is a 1 in 3 chance of receiving either the combination BAY60-4552 plus vardenafil, or vardenafil alone, or placebo. Neither patient nor the treating physician will know which treatment is given (double-blinded design).This part of the study will last four weeks Patients will have to go to the clinic/hospital for 7 visits during the 8 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Open-label run-in phase (first four weeks):

• Written informed consent signed before any study-specific procedure

• History of ED (Erectile Dysfunction) for at least 6 months prior to screening, defined as "the inability to achieve and maintain an erection of the penis sufficient to complete satisfactory sexual intercourse"; the diagnosis of ED has to be confirmed by a physician

• Stable, heterosexual relationship for at least 6 months prior to screening

• Aged 18 to 64 years (inclusive) at the first screening examination

• History of previous use of at least 1 marketed PDE5 (Phosphodiesterase 5) inhibitor and insufficient therapeutic efficacy despite use of the highest approved dose

• Double-blind treatment phase (last four weeks):

• At least 4 attempts at sexual intercourse on 4 separate days during the open-label run-in phase with use of 20 mg vardenafil approximately 1 hour before attempting intercourse

• IIEF EF (International Index of Erectile Function - Erectile Function subscale) score <17

• At least 50% of attempts at sexual intercourse during the open-label run-in phase were unsuccessful

Exclusion Criteria:

• Contraindication to use of vardenafil

• History of prostatectomy due to prostate cancer, including nerve-sparing techniques.

• Concomitant use of adrenergic blockers

• History of spinal cord injury

• Resting hypotension, i.e. SBP (Systolic Blood Pressure) <100 mmHg at rest

• Moderate / severe hypertension, i.e. SBP >170 mmHg or DBP >110 mmHg at rest

• Symptomatic orthostatic hypotension with a decrease in SBP >20 mmHg or in DBP (Diastolic Blood Pressure) >10 mmHg subsequent to change from the supine to standing position

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Erectile Dysfunction

Intervention

Drug:
• BAY60-4552 plus Vardenafil
Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
• Vardenafil
Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
• Placebo
Treatment with 3 tablets once daily for 4 weeks (Placebo)

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Finland,  France,  Germany,  Italy,  Netherlands,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Severity of erectile dysfunction assessed by the IIEF-EF (International Index of Erectile Function - Erectile Function subscale)		Week 4	No
Secondary	Success rate assessed by subject diary question: 'Maintenance' (Did your erection last long enough to have sexual intercourse?)		Week 4	No
Secondary	Success rate assessed by subject diary question: Penetration' (Were you able to insert your penis into your partner's vagina?)		Week 4	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information of Bayer products for Europe
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer Healthcare products.